Literature DB >> 12160857

Induced humoral immunity and vaccination against major human fungal pathogens.

Arturo Casadevall1, Marta Feldmesser, Liise-anne Pirofski.   

Abstract

Protection against fungal pathogens can theoretically be elicited by vaccines that stimulate humoral or cellular immunity, or both. There is conclusive evidence that humoral immunity can modify the course of infection against certain pathogenic fungi such as Candida albicans and Cryptococcus neoformans. However, for other fungi, such as Aspergillus fumigatus, the notion that humoral immunity contributes to host defence is unproven. Attempts to evaluate the potential efficacy of humoral immunity using immune sera are often inconclusive, whereas consistent results can be obtained with monoclonal antibodies. Protective monoclonal antibodies can be used to identify antigens that induce useful humoral responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160857     DOI: 10.1016/s1369-5274(02)00337-5

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  21 in total

1.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.

Authors:  Johanna Karlsson; Björn Andréasson; Nahid Kondori; Evelina Erman; Kristian Riesbeck; Harriet Hogevik; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

Review 3.  Adaptive immunity to fungi.

Authors:  Marcel Wüthrich; George S Deepe; Bruce Klein
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

4.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 5.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Toll-like receptor 4 signaling leads to severe fungal infection associated with enhanced proinflammatory immunity and impaired expansion of regulatory T cells.

Authors:  Flávio V Loures; Adriana Pina; Maíra Felonato; Eliseu F Araújo; Katia R M Leite; Vera L G Calich
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

7.  Humoral response against Cryptococcus neoformans mannoprotein antigens in HIV-infected patients.

Authors:  L Pitzurra; S Perito; F Baldelli; F Bistoni; A Vecchiarelli
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

8.  Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies.

Authors:  Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.

Authors:  Anna Rachini; Donatella Pietrella; Patrizia Lupo; Antonella Torosantucci; Paola Chiani; Carla Bromuro; Carla Proietti; Francesco Bistoni; Antonio Cassone; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

10.  The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity.

Authors:  Annemiek B van Spriel; Mariam Sofi; Kate H Gartlan; Alie van der Schaaf; Ineke Verschueren; Ruurd Torensma; Reinier A P Raymakers; Bruce E Loveland; Mihai G Netea; Gosse J Adema; Mark D Wright; Carl G Figdor
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.